OYE Therapeutics Begins Phase 2 Clinical Trial for Anesthesia Recovery Drug

OYE Therapeutics Inc. has officially begun a Phase 2 clinical trial to test the effectiveness of a new drug designed to help patients wake up from general anesthesia. The company announced on November 5, 2026, that the first patient has received a dose of the investigational treatment, known as OYE-101. This milestone follows the successful completion of an initial scientific bridging study. The trial is currently being conducted under an active Investigational New Drug application with the U.S. Food and Drug Administration. OYE Therapeutics is based in the Purdue Technology Center in Northwest Indiana. General anesthesia and deep sedation are standard procedures used in millions of surgeries every year. While these methods are safe, some patients experience delayed emergence or residual sedation after their operations. These complications can lead to respiratory issues and longer recovery times in the hospital. By addressing these challenges, the new drug aims to improve the overall experience for patients and healthcare providers. The Phase 2 study is expected to enroll approximately 40 adult surgical patients to gather necessary data. Researchers will evaluate how quickly patients regain alertness and their readiness for postoperative recovery. The trial will also monitor the safety and efficacy of the intravenous caffeine formulation. OYE Therapeutics is utilizing the FDA’s 505(b)(2) regulatory pathway for this development. This specific pathway allows companies to rely on existing findings for previously approved drugs while providing new clinical data for their specific use. This approach is intended to streamline the development process for new medical indications. The company believes that this novel formulation could meaningfully improve recovery outcomes. By reducing the time patients spend in a sedated state, hospitals may be able to manage resources more efficiently. The results of this trial will be critical in determining the next steps for the drug's development. As with all clinical trials, the final outcomes remain subject to the results of the study and future regulatory reviews.